These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose https://jasperitbp601181.arwebo.com/61433791/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide